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Background: Infantile wheezing is a common problem, but there are
no guidelines for the evaluation of infants with recurrent or persistent
wheezing that is not relieved or prevented by standard therapies.
Methods: An American Thoracic Society–sanctioned guideline
development committee selected clinical questions related to
uncertainties or controversies in the diagnostic evaluation of
wheezing infants. Members of the committee conducted
pragmatic evidence syntheses, which followed the Grading of
Recommendations, Assessment, Development, and Evaluation
(GRADE) approach. The evidence syntheses were used to inform
the formulation and grading of recommendations.
Results: The pragmatic evidence syntheses identified few studies
that addressed the clinical questions. The studies that were identified
constituted very low-quality evidence, consisting almost exclusively
of case series with risk of selection bias, indirect patient populations,
and imprecise estimates. The committee made conditional
recommendations to perform bronchoscopic airway survey,
bronchoalveolar lavage, esophageal pHmonitoring, and a swallowing
study. It alsomade conditional recommendations against empiric food
avoidance, upper gastrointestinal radiography, and gastrointestinal
scintigraphy. Finally, the committee recommended additional
research about the roles of infant pulmonary function testing and food
avoidance or dietary changes, based on allergy testing.
Conclusions: Although infantile wheezing is common, there is a
paucity of evidence to guide clinicians in selecting diagnostic tests
for recurrent or persistent wheezing. Our committee made several
conditional recommendations to guide clinicians; however, additional
research that measures clinical outcomes is needed to improve our
confidence in the effects of various diagnostic interventions and to
allow advice to be provided with greater confidence.
Overview
Wheezing occurs commonly during infancy
(1). In most cases, wheezing episodes are
mild and easily treated (2). However,
some infants will develop persistent or
recurrent wheezing, which is often severe
(3). These infants are frequently referred
to pediatric pulmonology specialists
for further evaluation and treatment.
Guidelines for diagnostic testing exist for
older children with asthma (4), but such
guidelines are lacking for wheezing infants.
In a 2009 survey of Assembly on Pediatrics
members of the American Thoracic Society
(ATS), infantile wheezing was one of the
highest ranked topics for which members
desired a guideline. To address this
knowledge gap and interest, the ATS
convened a committee of pediatric
pulmonologists with clinical and research
experience in infantile wheezing to develop
evidence-based guidelines for the diagnostic
evaluation of infantile wheezing.
For these guidelines, the committee
defined infantile wheezing as recurrent or
persistent episodes of wheezing in infants
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Limitations and Future Directions
less than 24 months old (herein referred to
as “infants with persistent wheezing”). The
guidelines address diagnostic tests that
are frequently considered by pediatric
pulmonologists and other clinicians when
evaluating infantile wheezing, but are either
controversial or a frequent source of
uncertainty. Diagnostic tests that are
generally considered standard of care (e.g.,
chest radiography) were not addressed.
The committee performed a pragmatic
evidence synthesis and then used the
Grading of Recommendations, Assessment,
Development, and Evaluation (GRADE)
approach (5) to formulate and grade the
following recommendations:
1. For infants with persistent wheezing
despite treatment with bronchodilators,
inhaled corticosteroids, or systemic
corticosteroids, we suggest an airway
survey via flexible fiberoptic bronchoscopy
(conditional recommendation, very low
quality of evidence).
2. For infants with persistent wheezing despite
treatment with bronchodilators, inhaled
corticosteroids, or systemic corticosteroids,
we suggest bronchoalveolar lavage (BAL)
(conditional recommendation, very low
quality of evidence).
3. We recommend research studies in
infants with persistent wheezing despite
treatment with bronchodilators, inhaled
corticosteroids, or systemic corticosteroids,
which compare clinical outcomes among
those who are managed according to
results of infant pulmonary function
testing using the raised-volume rapid
thoracoabdominal compression (RVRTC)
method versus those who are managed
according to clinical assessment alone.
4. A. For infants who do not have eczema
but have persistent wheezing despite
treatment with bronchodilators,
inhaled corticosteroids, or systemic
corticosteroids, we suggest that
clinicians and caregivers not use
empiric food avoidance or dietary
changes (conditional recommendation,
very low quality of evidence).
B. We recommend research studies that
determine whether food avoidance or
dietary changes guided by food allergy
testing improves clinical outcomes
in infants who do not have eczema
but have persistent wheezing despite
treatment with bronchodilators,
inhaled corticosteroids, or systemic
corticosteroids.
5. For infants with persistent wheezing
despite treatment with bronchodilators,
inhaled corticosteroids, or systemic
corticosteroids, we suggest 24-hour
esophageal pH monitoring (conditional
recommendation, very low quality of
evidence).
6. For infants with persistent wheezing
despite treatment with bronchodilators,
inhaled corticosteroids, or systemic
corticosteroids, we suggest 24-hour
esophageal pH monitoring rather than
upper gastrointestinal radiography
(conditional recommendation, very low
quality of evidence).
7. For infants with persistent wheezing
despite treatment with bronchodilators,
inhaled corticosteroids, or systemic
corticosteroids, we suggest 24-hour
esophageal pH monitoring rather
than gastrointestinal scintigraphy
(conditional recommendation, very low
quality of evidence).
8. For infants with persistent wheezing
despite treatment with bronchodilators,
inhaled corticosteroids, or systemic
corticosteroids, we suggest performing
video-fluoroscopic swallowing studies
(conditional recommendation, very low
quality of evidence).
Introduction
Wheezing during infancy is a common
clinical problem. In the Tucson Children’s
Respiratory Study, a longitudinal birth
cohort study of healthy full-term infants,
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34% of children had at least one episode of
wheezing before age 3 years (1). In some
infants, this is a sign of early-onset asthma
(6), whereas other infants may wheeze
because of diminished airway function or
innate immune responses (7, 8). For the
majority of infants, these wheezing episodes
are mild, episodic, and easily treated.
However, some infants will develop severe
recurrent or persistent wheezing. Guidelines
for the evaluation and treatment of asthma
in older children and the general approach
to the evaluation of infantile wheezing have
been published (4, 9), but no guidelines exist
for the use of more specialized testing, such
as flexible fiberoptic bronchoscopy, in the
evaluation of infants with persistent
wheezing. Recognizing the need for clinical
guidance on the diagnostic evaluation of
wheezing infants, the ATS convened a
guideline development committee of
pediatric specialists to conduct pragmatic
evidence syntheses and then use the evidence
syntheses as the basis for recommendations
for the evaluation of persistent wheezing
in infancy.
Use of These Guidelines
These ATS guidelines are not meant to
establish a standard of care. Rather,
they represent an effort to summarize
evidence and provide reasonable clinical
recommendations based on that evidence.
Clinicians, patients, third-party payers,
other stakeholders, and the courts should
never view these recommendations as
dictates. No guidelines or recommendations
can take into account all of the often
compelling, unique individual clinical
circumstances. Therefore, no one charged
with evaluating clinicians’ actions should
attempt to apply the recommendations
from these guidelines by rote or in a blanket
fashion. These guidelines are not intended
to be a comprehensive review of the
evaluation of infantile wheezing, but
rather to provide evidence-based
recommendations for a set of specialized
diagnostic tests frequently considered in the
evaluation of this patient population.
Clinicians will be able to use these
recommendations when considering
specific diagnostic tests for the evaluation of
persistent wheezing. Recommendations
for order or selection of diagnostic testing
are beyond the scope of this document, and
such decisions will vary depending on




For these guidelines, the committee
defined infantile wheezing as recurrent or
persistent episodes of wheezing in infants
less than 24 months old (herein, referred to
as “infants with persistent wheezing”).
This cutoff was chosen for two reasons:
previous documents have addressed
wheezing in preschool-aged children
(3–5 yr old) (10), and wheezing on the basis
of diminished airway function tends to
improve by age 3 years (1). The population
was further limited to infants with
persistent wheezing despite treatment with
recommended first-line therapies of
bronchodilators, inhaled corticosteroids, or
systemic corticosteroids (11).
Process
The co-chairs (C.L.R. and C.R.E.) were
confirmed by the ATS Assembly on
Pediatrics, Program Review Subcommittee,
and Board of Directors. A guideline
development committee was then assembled,
which consisted of pediatric clinicians and
researchers with expertise in the evaluation of
wheezing during infancy. All members of the
committee disclosed and were vetted for
potential conflicts of interest according to the
rules and procedures of the ATS. The
committee then developed clinical questions,
using the PICO (Patient, Intervention,
Comparator, and Outcomes) framework.
Each question was the basis of a pragmatic
evidence synthesis, which consisted of
searching the Medline and CINAHL
(Cumulative Index to Nursing and Allied
Health Literature) databases on the basis of
prespecified search criteria, selecting studies
based on prespecified selection criteria, and
appraising and summarizing the evidence
according to the GRADE approach. The
evidence syntheses were used as the basis for
the formulation of recommendations, which
was based on consideration of the balance of
benefits versus harms and burdens, quality of
evidence, patient preferences, and cost and
resource use. The recommendations were
graded according to the GRADE approach.
The specifics of the PICO framework,
outcomes, and other methods are
described in greater detail in the online
supplement.
Results
Question 1: Should Infants with
Persistent Wheezing despite
Treatment with Bronchodilators,
Inhaled Corticosteroids, or Systemic
Corticosteroids Undergo Airway
Survey via Flexible Fiberoptic
Bronchoscopy?
Summary of evidence. Our literature search
did not identify any studies that compared
wheezing infants undergoing airway survey via
bronchoscopy with wheezing infants who did
not undergo airway survey. Therefore, our
recommendation is based on 10 case series
that collectively included 1,364 patients and
reported that 452 of the 1,364 patients (33%)
who underwent airway survey for respiratory
symptoms were found to have an anatomic
abnormality known to cause wheezing
(Table 1) (12–21). Lesions included
tracheomalacia, bronchomalacia,
tracheobronchomalacia, vascular rings,
vascular slings, and airway compression by a
vascular structure. No major complications
were reported in any of the case series, with
minor complications such as transient
hypoxemia described in 5–10% of subjects.
Infants with wheezing due to
tracheomalacia, bronchomalacia, or
tracheobronchomalacia are typically
managed by observation alone if wheezing is
the only abnormality or the associated
symptoms are mild, because the vast
majority of infants improve over time
with conservative therapy (22). Infants
with wheezing due to tracheomalacia,
bronchomalacia, or tracheobronchomalacia
occasionally require an intervention
(e.g., positive airway pressure, surgery, or
stenting) because of accompanying life-
threatening airway obstruction, respiratory
failure, recurrent pneumonias, or failure
to thrive. Positive airway pressure
immediately decreases respiratory distress,
restores airway patency, and improves
pulmonary function according to multiple
small case series and case reports (23–30).
Surgery (most commonly, aortopexy)
relieves obstruction in virtually all patients
with tracheomalacia, but is less effective in
patients with tracheobronchomalacia or
bronchomalacia according to small case
series (31–37). This was illustrated by a case
series in which 21 of 21 patients (100%)
had tracheomalacia corrected by aortopexy,
but only 1 of 4 patients (25%) with
AMERICAN THORACIC SOCIETY DOCUMENTS










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































AMERICAN THORACIC SOCIETY DOCUMENTS
American Thoracic Society Documents 359
 
tracheobronchomalacia was corrected by
aortopexy (31). Airway stenting has been
used to improve airway obstruction in
infants (38–42), but complications
including formation of granulation tissue,
migration, or erosion occurred in 50% of
cases and were potentially associated
with death in 2 of 22 infants (39, 40).
Newer approaches include direct
tracheobronchopexy (43).
In contrast, wheezing due to vascular
rings, vascular slings, and airway
compression by a vascular structure is
unlikely to self-resolve, and surgical
correction is performed for symptomatic
patients. According to seven case series,
improvement in respiratory symptoms
was seen in 88–100% of patients, and
complete resolution was seen in more than
50% of patients. Recurrent laryngeal nerve
injury was the most common surgical
complication and occurred in less than 10%
of patients. More serious complications such
as aortoesophageal fistula, heart failure, or
wound infection associated with mortality
occurred in less than 5% of patients (44–50).
Taken together, the evidence indicates
that an anatomic abnormality known to
cause wheezing can be identified by airway
survey in approximately 33% of patients
with respiratory symptoms, and in the
committee’s clinical experience more than
90% of such patients will improve because
either their condition is self-limited or
surgery can correct the abnormality.
Thus, about 30% of patients are likely to
benefit from an airway survey, either
through direct intervention (surgery) or by
avoiding unnecessary tests and treatments
for a benign, self-limited condition.
Identification of airway malacia may also
help in management of infants believed
to have concomitant asthma, because
b-agonists may adversely affect airway
dynamics in these children (51). The
committee has very low confidence
(i.e., quality of evidence) in the accuracy of
these estimated effects, because the case
series had probable selection bias and most
series looked at infants who underwent
bronchoscopy for respiratory symptoms,
not specifically wheezing.
Rationale. Bronchoscopy with airway
survey that identifies an anatomical cause of
wheezing confers several potential benefits.
Finding tracheomalacia, bronchomalacia, or
tracheobronchomalacia usually leads to
conservative management, which has a high
success rate and other benefits including
relief from the burden, cost, and potential
harms of further diagnostic testing; probable
reductions in the use of ineffective
medications (bronchodilators or systemic
corticosteroids) and the frequency of
physician visits; and parental reassurance,
given the high likelihood that the condition
will spontaneously resolve. Finding
vascular rings, vascular slings, and airway
compression by a vascular structure leads to
surgical therapy with an 88–100% success
rate. In the judgment of the committee,
the possibility that approximately 30% of
infants who undergo airway survey will
benefit far exceeds the burdens and cost
of bronchoscopy, as well as the potential
harms (i.e., complications due to
bronchoscopy are rare and complications due
to subsequent therapy range from zero for
conservative management to approximately
10% for surgery). The recommendation for
airway survey is conditional because the low
quality of evidence provides little certainty
that the benefits of airway survey exceed the
burdens, costs, and harms. There are also
emerging data on neurodevelopmental risks
of anesthesia that need to be considered (52).
In addition, parental preferences regarding
invasive procedures tend to be highly
individualized.
Recommendation 1. For infants with
persistent wheezing despite treatment with
bronchodilators, inhaled corticosteroids, or
systemic corticosteroids, we suggest airway
survey via flexible fiberoptic bronchoscopy
(conditional recommendation, very low
quality of evidence).
Question 2: Should Infants with
Persistent Wheezing despite
Treatment with Bronchodilators,
Inhaled Corticosteroids, or Systemic
Corticosteroids Undergo
Bronchoalveolar Lavage?
Summary of evidence. Our literature search
did not identify any studies that compared
wheezing infants undergoing BAL with
wheezing infants who did not undergo BAL.
Therefore, our recommendation is based on
data from 20 case series, identified in our
literature search, showing that 14–80% of
infants (40–60% in most studies) with
recurrent or persistent wheezing produce a
positive BAL culture (Table 2) (12, 16, 18,
53–70). No complications were reported in
any of the case series.
Patients with a positive BAL culture
typically receive a prolonged course of
antibiotic therapy, and indirect evidence
from a randomized trial of 50 children with
productive cough presumed to be caused by
bacterial bronchitis found that the cough
resolved in 48% of children who received
antibiotic therapy, compared with only 16%
of those who did not receive antibiotics (71).
The trial likely underestimated the effects
of antibiotics in patients with bacterial
bronchitis because children did not need to
have a confirmed bacterial infection to be
enrolled in the trial; patients without
bacterial bronchitis are unlikely to have
responded to antibiotic therapy and,
therefore, their inclusion would have made
antibiotic therapy appear less effective.
On the basis of the rates of BAL
infection (40–60%) and symptom
improvement with antibiotic treatment
(48%) described previously, we estimate
that 20–30% of children with persistent
wheezing who undergo bronchoscopy with
BAL will be found to have a lower airway
bacterial infection and that their symptoms
will improve with antibiotic therapy. The
committee’s confidence in the estimated
effects of BAL (i.e., the quality of evidence)
is very low because it is based on prevalence
estimates derived from case series and
a therapeutic effect estimated from a
randomized trial, both of which had serious
limitations. The case series were limited
by selection bias, indirectness of the
population (children with cough rather
than infants with wheezing), and small
sample sizes with few events. The
randomized trial was similarly limited by
indirectness of the population (children
with cough rather than infants with
wheezing), indirectness of the outcome
(cure of infection rather than improvement
in wheezing), and imprecision (small
sample size with few events).
Rationale. To confirm or exclude lower
airway bacterial infection as the cause of
recurrent or persistent wheezing, clinicians
have three options: (1) they can perform
BAL and then treat patients with confirmed
bacterial infection with antibiotics;
(2) they can empirically treat all patients
with empiric antibiotics; or (3) they can do
neither. The committee judged the balance
of the benefits versus the burdens and
risks to be greater for the first option
(i.e., 20–30% children improve after
treatment of BAL-identified infection) than
for either the second option (i.e., the
same infection cure rate, but 40–60% of
patients receive unnecessary antibiotics
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with their associated risks, such as fever,
rash, anaphylaxis, acquisition of resistance,
and change in gut microbiome [72]) or third
option (i.e., only 6.4–9.6% infection cure
rate). The committee recognized that the
estimated cure rates for lower respiratory
infection likely overestimate the cure rate for
wheezing because some infants with lower
respiratory tract bacterial infection have
additional or alternative causes of wheezing;
nonetheless, the committee still thought
that the risk of BAL is sufficiently small
that the benefits probably outweigh the
burdens and harms.
The strength of the recommendation
for BAL is conditional because the
committee’s very low confidence in the
estimated effects of BAL made it impossible
to be certain that the benefits of BAL
outweigh the risks and burdens in the
majority of patients. Moreover, BAL
requires bronchoscopy, an invasive
procedure requiring sedation, and it is
uncertain that most families would want
bronchoscopy performed on their infant,
despite persistent wheezing.
Recommendation 2. For infants with
persistent wheezing despite treatment with
bronchodilators, inhaled corticosteroids, or
systemic corticosteroids, we suggest BAL
(conditional recommendation, very low
quality of evidence).
Question 3: Should Infants
with Persistent Wheezing
despite Treatment with Bronchodilators,
Inhaled Corticosteroids, or Systemic
Corticosteroids Be Managed
according to the Results of Infant
Pulmonary Function Testing Using
the Raised-Volume Rapid
Thoracoabdominal Compression
Technique or Clinical Assessment
Alone?
Summary of evidence. Our literature search
revealed 1,261 studies related to wheezing
and pulmonary function tests (PFTs) in
children. The overwhelming majority (1,226
studies) were excluded because they enrolled
children during later childhood, and the
guideline development committee believed
that such evidence was too indirect to inform
judgments for infants. Among the 35 studies
that involved PFTs performed during
infancy, only 2 (from the same cohort of
patients at two different time points)
described clinical outcomes after
the assessment of bronchodilator
responsiveness (BDR) using the RVRTC
technique (73, 74). Both studies reported
that the presence of BDR identified by the
RVRTC technique predicted future acute
exacerbations of wheezing requiring
treatment with systemic corticosteroids. No
studies were identified that compared the
effects of management according to the BDR
measured by the RVRTC technique versus
management based on clinical assessment
alone (i.e., no PFTs) on the clinical outcomes
of interest (frequency of wheezing, frequency
of doctor visits, frequency of hospitalization,
prescriptions for bronchodilators,
prescriptions for inhaled or systemic
corticosteroids, parental stress, additional
diagnostic testing, and inappropriate
therapy). Thus, there was no published
evidence available to inform the guideline
development committee’s judgments.
Rationale. In the absence of published
evidence, the guideline development
committee turned to its collective clinical
experience to try to answer the question.
However, despite extensive discussion, the
guideline development committee could
not reach consensus on a clinical
recommendation for or against infant PFTs,
due to the paucity of evidence. Some
members of the committee believed that the
information derived from infant PFTs did
not justify the burdens and risks involved in
performing the test. Among the potential
benefits of confirming or excluding BDR,
the clinician may be directed away or toward
diagnostic testing that targets anatomical
causes of wheezing, respectively. Among the
risks and burdens of such testing are the
need for sedation; the risks associated with
airway occlusion, gastric distention, and
aerophagia; the additional personnel needed
to monitor the infant during and after the
test; and the time and personnel needed to
set up and conduct the test. Other members
of the guideline development committee
believed that there are circumstances in
which infant PFTs are clinically useful. For
example, a restrictive pattern on the PFT
might lead clinicians to explore interstitial
lung disease, andmarked gas trapping might
motivate clinicians to evaluate the infant
further for neuroendocrine hyperplasia of
infancy, although wheezing is usually not a
common feature of this condition (75).
Recommendation 3. In infants with
persistent wheezing despite treatment
with bronchodilators, inhaled
corticosteroids, or systemic corticosteroids,
we recommend research studies that
compare clinical outcomes among infants
who are managed according to infant PFT
performed using the RVRTC technique
versus those who are managed according to
clinical assessment alone.
Question 4: Should Infants without
Eczema Who Have Persistent





Summary of evidence. The National
Institute of Allergy and Infectious Diseases
has published clinical guidelines on food
allergy in children with eczema, including
recommendations for food allergy testing
and avoidance in infants and children with
this condition (76). Therefore, we focused
our question on the role of food avoidance
in infants without eczema. Our systematic
review identified four studies that assessed
the results of empiric food avoidance
(Table 3). All of the studies measured our
prespecified outcome of frequency of
wheezing, but none measured any of our
other prespecified outcomes, including
frequency of doctor visits, frequency of
hospitalization, prescriptions for
bronchodilators, prescriptions for inhaled
or systemic corticosteroids, parental
stress, additional diagnostic testing, and
inappropriate therapy. A trial randomly
assigned 487 infants to receive either a
cow’s milk–free diet or a usual diet for at
least the initial 4 months of life and found
no difference in wheezing, eczema, or
nasal discharge at 1 year (77). Four
hundred and forty-six of the infants were
reassessed 6 years later. There were still
no differences in the incidence of
wheezing, asthma diagnoses, eczema, or
allergic rhinitis (78). Another trial
randomly assigned 110 infants to receive
either a partially hydrolyzed formula or
standard infant formula for the first
4 months of life. There was no difference
in the incidence of wheezing at 2 years,
although eczema was more common
among the infants who received a
standard formula (79). Finally, a
prospective cohort study monitored 6,905
newborns through preschool age and
found no relationship between the early
introduction of potentially allergenic
foods (e.g., cow’s milk, egg, nuts, soy, or
gluten) and either wheezing or eczema at
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ages 2, 3, and 4 years. The study plans to
monitor the participants to adulthood (80).
None of the studies evaluated the effects of
empiric food avoidance in a subgroup of
food antigen IgE–positive infants.
Taken together, the evidence suggests
that empiric food avoidance has no effect
on the frequency of wheezing. However, it
provides very low confidence (i.e., quality of
evidence) in the estimated effects because the
randomized trials were limited by risk of bias,
indirectness of population and intervention,
and imprecision, and the observational study
was limited by possible recall bias.
Rationale. The guideline development
committee chose to include questions
regarding food avoidance and allergy testing
because in the collective experience of the
committee, parents of infants with persistent
wheezing frequently raise this topic.
Although there is evidence that respiratory
symptoms can be provoked by food antigens
in infants with eczema (81), less is known
about this relationship in infants without
eczema. The guideline development
committee’s judgments were based on the
impact of empiric food avoidance on
frequency of wheezing, because our other
prespecified outcomes were not reported.
The lack of beneficial effects due to empiric
food avoidance in any study, combined
with the committee’s recognition
that empiric food avoidance can be
burdensome, led the committee to suggest
that empiric food avoidance not be used in
infants without eczema who have persistent
wheezing despite standard therapy. The
strength of the recommendation is
conditional because the very low quality of
evidence prevented the committee from
being certain about its judgments. In other
words, although the committee believes
that there is no evidence that the desirable
consequences of empiric food avoidance
outweigh the undesirable consequences in
the majority of patients, it recognizes that
there may be clinical circumstances in
which a trial of empiric food avoidance may
be reasonable for a minority of patients
for whom the clinical history strongly
correlates respiratory symptoms with food
exposure or in whom respiratory symptoms
are elicited in a double-blind placebo-
controlled food challenge.
Recommendation 4.
A. For infants without eczema who have
persistent wheezing despite treatment
with standard therapies, we suggest
not using empiric food avoidance
(conditional recommendation, very low
quality of evidence).
B. We recommend research to determine
whether or not empiric food avoidance is
beneficial for the subgroup of infants
who are positive for IgE to food antigens.
Question 5: Should Infants with
Persistent Wheezing despite
Treatment with Bronchodilators,
Inhaled Corticosteroids, or Systemic
Corticosteroids Undergo 24-Hour
Esophageal pH Monitoring?
Summary of evidence. Our systematic review
did not identify any randomized trials
or controlled observational studies
that compared clinical outcomes among
those who underwent 24-hour esophageal
pH monitoring versus those who did
not. However, we did identify three case
series that used 24-hour pH monitoring
to determine the prevalence of
gastroesophageal reflux (GER) among
children with wheezing and also reported the
clinical outcomes that followed treatment
of those with confirmed GER (Table 4)
(82–84).
The most recent case series (83)
enrolled 25 infants and children with
asthma (88% had persistent wheezing)
and performed 24-hour pH monitoring
on all participants. GER was identified in
19 of 25 (76%) infants and children.
Participants with GER were treated
with a proton pump inhibitor and
reassessed at 3 months, at which time
there were statistically significant
improvements in symptoms (from 2.3
to 0.4 symptoms per day), use of
bronchodilators (from 8.3 to 1.4 d per
patient), use of systemic steroids (from
5.3 to 0.4 d per patient), frequency
of exacerbations (from 1.5 to 0.3
exacerbations per patient), and
hospitalizations (from 9.1 to 0.5 d
per patient) compared with before
treatment.
The case series confirmed three earlier
series. In the first (82), 36 infants and
children with various respiratory disorders
underwent 24-hour pH monitoring. GER
was identified in 22 of 36 infants and
children (61%) , including 4 of 6 infants
and children (67%) with wheezing. Among
those 22 patients, 9 patients underwent
fundoplication, after which symptoms
improved in 6 and resolved in 3. The
remaining 13 patients with GER were
treated with medical management; 9 had
symptomatic improvement and 4 were lost
to follow-up. In the second series (84), 12
infants with persistent wheezing despite
bronchodilator and antiinflammatory
therapy underwent 24-hour pH
monitoring, and all were confirmed to
have GER. They were subsequently treated
with prokinetic agents and histamine
receptor blockers; six improved enough to
no longer require antiasthma medications,
two improved enough that they required
only intermittent antiasthma medications,
and four failed to improve and underwent
fundoplication. After fundoplication,
three of the four patients no longer
required antiasthma medications. In the
third series (85), 81 children with
recurrent pneumonias or chronic asthma
underwent 24-hour pH monitoring, and
38 (47%) were found to have GER. Forty
patients were treated for GER (2 on the
basis of alternative tests). Among the
12 children who underwent medical
management, 10 improved (83%). Among
the 24 children who underwent surgical
treatment, 22 improved (92%). Four
patients were lost to follow-up. None of
the case series reported any adverse effects
from the 24-hour pH monitoring or
subsequent therapy.
Taken together, the evidence indicates
that GER exists in 47–100% of infants with
persistent wheezing and, if identified, more
than 83% (most estimates are in the
90–100% range) will improve with medical
or surgical treatment. However, the
evidence provides very low confidence in
the estimated effects. With respect to
indirectness of the population, most studies
included older children with a mix of
respiratory problems in addition to
wheezing (e.g., recurrent pneumonia,
apnea, stridor, and cough) and did not
evaluate the wheezing infant subgroup.
With respect to indirectness of the
intervention, there was variability in the
methods used for 24-hour pH monitoring,
including positioning of probes, patient
positioning, dietary restrictions, scoring
criteria, definitions of an abnormal study,
and use of impedance data. pH probes
detect only acid reflux unless paired with
impedance; thus, not using impedance
data may underestimate episodes of
postprandial reflux in infants with frequent
feeds and buffering of gastric contents (86).
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Rationale. The guideline development
committee believed that the balance of
benefits versus risks, burdens, and cost
favors 24-hour pH monitoring in
most infants who have persistent
wheezing despite bronchodilator and
antiinflammatory therapy. Specifically,
among such infants who undergo 24-hour
pH monitoring, 67–100% will be found to
have GER and nearly all will improve
substantially with treatment, without
requiring further diagnostic testing. The
procedure is well tolerated by the vast
majority of patients and, although its
semiinvasive nature and potential
need for inpatient admission may be
concerning to some parents, the
committee believed that most families
would be willing to have the test done.
Although combined pH and impedance
probe monitoring has become the standard
at most centers, the available evidence
largely predates widespread use of
impedance probes. Therefore, the committee
was unable to comment specifically on the
value of impedance monitoring.
An alternative to 24-hour pH
monitoring is an empiric trial of antiacid
therapy. However, in up to one-third
patients receiving empiric therapy, the
antiacid therapy is inappropriate and incurs
unnecessary cost, burden, and risk. In
addition, the rate of treatment success is
likely to be lower among empirically treated
patients because those with GER that
requires fundoplication may be incorrectly
considered nonresponders. In that case, it
may be presumed that GER is not a
contributor and the parents may never be
offered potentially curative surgical therapy.
Furthermore, studies in older patients
suggest that proton pump inhibitor therapy
is linked to increased risk of pneumonia
(87). Although a similar risk has not
been reported in infants, a normal pH-
monitoring study could potentially reduce
any risks associated with proton pump
inhibitor therapy.
The strength of our recommendation is
conditional because the very low quality of
evidence provided little confidence in the
estimated benefits and harms reported by
the case series. As a result, the committee
could not be certain about its judgments
regarding the balance of benefits versus
harms, burdens, and cost.
Recommendation 5. For infants with
persistent wheezing that is not relieved by
bronchodilators, inhaled corticosteroids, or
systemic corticosteroids, we suggest 24-hour
esophageal pH monitoring (conditional
recommendation, very low quality of
evidence).
Question 6: Should Infants
with Persistent Wheezing despite
Treatment with Bronchodilators,
Inhaled Corticosteroids, or Systemic
Corticosteroids Undergo an Upper
Gastrointestinal Series Rather Than
24-Hour Esophageal pH Monitoring?
Summary of evidence. The guideline
development committee next asked whether
an upper gastrointestinal (UGI) series is an
acceptable alternative to 24-hour esophageal
pH monitoring, which we considered the
reference standard. Our systematic review
did not identify any randomized trials or
controlled observational studies that
compared clinical outcomes among those
who underwent a UGI series with those who
underwent 24-hour esophageal pH
monitoring. However, it did identify three
studies that evaluated the accuracy of a UGI
series in detecting GER in infants and children
with wheezing (Table 4) (82, 85).
In the only study that used 24-hour pH
monitoring as the reference standard, 79
children (age, 2–17 yr) who had difficult-
to-control asthma underwent 24-hour
esophageal pH monitoring. GER was
identified in 58 of 79 children (73%). A
barium swallow study was then performed,
which identified GER with a sensitivity
and specificity of 46 and 82%, respectively
(88).
The other two studies used various
reference standards, but reported enough
data to enable us to estimate the sensitivity
of a UGI series in the detection of GER
relative to 24-hour esophageal monitoring.
In a study of infants and children (age,
2 mo–10.5 yr) with recurrent respiratory
disorders (82), 22 of 36 (61%) were found
to have GER by 24-hour pH monitoring,
and 15 of 35 (42%) were found to have
GER by UGI series. Assuming that patients
in whom GER was detected by UGI series
also had GER detected by 24-hour pH
monitoring, the sensitivity of a UGI series
would be 68%. In a study of 82 infants and
children (5 mo–16 yr) with recurrent
pneumonia or chronic asthma (85), 40 were
found to have GER on the basis of study
criteria; of these, 30 of 40 had positive UGI
series results and 38 of the 39 infants who
had 24-hour pH monitoring showed
positive results (one patient did not
undergo pH monitoring). On the basis of
these numbers, the sensitivity of a UGI
series would be 75%, compared with 97%
for pH monitoring. The sensitivity of a UGI
series appears to be similarly poor among
children without respiratory symptoms
(89).
These accuracy tests constitute very
low-quality evidence, meaning that they
provide very low confidence in their results.
The poor quality of evidence reflects the
fact that the studies did not enroll
consecutive patients, and it was not reported
whether there was legitimate uncertainty
about the presence or absence of GER.
Rationale. The primary advantages of
performing a UGI series rather than 24-hour
esophageal pH monitoring are that a UGI
series can be performed less invasively and in
less time. A less frequent advantage is that
UGI series occasionally demonstrate
pertinent anatomical abnormalities, such as
hiatal hernias or esophageal indentation
suggestive of a vascular ring. The
disadvantages of a UGI series include
radiation exposure, the need for patient
cooperation, and its semiinvasive nature.
The guideline development committee
made the a priori decision that the benefits
of a UGI series would outweigh both the
disadvantages of a UGI series and the
consequences of incorrect results if
the false-negative rate was less than 10%
(i.e., sensitivity greater than 90%) and the
false-positive rate was less than 10%
(i.e., specificity greater than 90%). In other
words, assuming a prevalence of GER of
roughly 60%, the committee would accept
40 false-positive results and 60 false-
negative results for every 1,000 patients
tested. The acceptable false-negative and
false-positive rates are both relatively small
because 24-hour pH monitoring is not
overly risky or burdensome.
The evidence indicates that the
sensitivity (68–79%) and specificity (82%)
of UGI series are insufficient to warrant the
use of UGI series as an alternative to
24-hour esophageal pH monitoring. The
recommendation against UGI series is
conditional because the very low quality of
evidence does not provide sufficient
confidence in the estimated sensitivity and
specificity to be certain that a UGI series
is not a worthwhile alternative. The
meaning of a conditional recommendation
is that it is right for most patients, but
may not be right for a sizable minority
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in certain situations. As an example, a
UGI series can be a valuable tool for
identifying vascular rings or slings and may
be considered if such malformations
are suspected. A UGI series can also be
considered in circumstances in which
24-hour pH monitoring is not a practical
option.
Recommendation 6. For infants with
persistent wheezing that is not relieved by
bronchodilators, inhaled corticosteroids,
or systemic corticosteroids, we suggest
24-hour esophageal pH monitoring
rather than a UGI series (conditional
recommendation, very lowquality of evidence).
Question 7: Should Infants with
Persistent Wheezing That Is Not




Rather Than 24-Hour Esophageal pH
Monitoring?
Summary of evidence. The guideline
development committee next asked whether
gastroesophageal scintigraphy is an
acceptable alternative to 24-hour pH
monitoring, which we considered the
reference standard. Our systematic review
did not identify any randomized trials or
controlled observational studies that
compared clinical outcomes among those
who underwent scintigraphy with those who
underwent 24-hour esophageal pH
monitoring. However, it did identify four
studies that evaluated gastroesophageal
scintigraphic detection of GER in infants
and children with wheezing.
In the only study that used 24-hour
pH monitoring as the reference standard,
79 children (age, 2–17 yr) who had
difficult-to-control asthma underwent
24-hour esophageal pH monitoring.
Gastroesophageal scintigraphy identified
GER with a sensitivity and specificity of
15 and 73%, respectively (88). Another
study of infants with wheezing used clinical
history and a response to anti-GER therapy
as the reference standard instead of
24-hour pH monitoring. It found that
gastroesophageal scintigraphy detected
GER with a sensitivity and specificity of
58 and 85%, respectively, when a history
compatible with GER was used as the
reference standard, and with a sensitivity
and specificity of 79 and 50%, respectively,
when a response to anti-GER therapy
was used as the reference standard (90).
Finally, two studies did not compare
gastroesophageal scintigraphy with a
reference standard, but rather, reported
that the technique identified GER in 22%
of infants and children (age, 3 mo–4 yr)
who presented with recurrent wheezing
or vomiting (91) and in 26% of infants
and children (age, 6 mo–6 yr) who
presented with difficult-to-treat asthma
(92); these yields were lower than the
67–100% described previously for 24-hour
esophageal pH monitoring. The sensitivity
of gastroesophageal scintigraphy appears to
be similarly poor among infants and
children without respiratory symptoms
(89).
These accuracy studies constitute very
low quality of evidence, meaning that they
provide very low confidence in their
estimated effects. The poor quality of
evidence reflects the fact that the studies did
not enroll consecutive patients, and it was
not reported whether there was legitimate
uncertainty about the presence or absence of
GER. Moreover, there was indirectness of
the population because our focus was on
wheezing infants, but many of the studies
enrolled older children.
Rationale. The primary advantages of
gastroesophageal scintigraphy rather
than 24-hour esophageal pH monitoring
are that scintigraphy can be performed
less invasively and in less time. The
disadvantages of scintigraphy are
primarily radiation exposure (albeit less
than that required for a UGI series) and
high cost.
The guideline development committee
made an a priori decision that the advantages
of gastroesophageal scintigraphy would
outweigh the disadvantages associated with
potential incorrect results if the false-negative
rate was less than 10% (i.e., sensitivity greater
than 90%) and the false-positive rate was less
than 10% (i.e., specificity greater than 90%).
In other words, assuming a prevalence of
GER of roughly 60%, the committee would
accept 40 false-positive results and 60 false-
negative results for every 1,000 patients
tested. The acceptable false-negative and
false-positive rates are both relatively small
because 24-hour pH monitoring is not overly
risky or burdensome.
The evidence indicates that the
sensitivity and specificity (15 and 73%,
respectively) of gastroesophageal
scintigraphy are insufficient to warrant the
use of scintigraphy as an alternative to
24-hour esophageal pH monitoring. The
recommendation against scintigraphy is
conditional because the very low quality
of evidence does not provide sufficient
confidence in the estimated sensitivity and
specificity to be certain that scintigraphy is
not a worthwhile alternative.
Recommendation 7. For infants with
persistent wheezing that is not relieved by
bronchodilators, inhaled corticosteroids, or
systemic corticosteroids, we suggest 24-hour
esophageal pH monitoring rather than
gastrointestinal scintigraphy (conditional
recommendation, very low quality of
evidence).
Question 8: Should Infants without
Neurologic Pathology with Persistent





Summary of evidence. Our literature review
did not identify any randomized trials or
controlled observational studies that
compared clinical outcomes among
those who underwent a swallowing function
study versus those who did not. However, it
did identify two case series that reported the
prevalence of aspiration detected by
video-fluoroscopic swallowing function
studies in infants and children who did
not have chronic illnesses but did have
respiratory symptoms including wheezing
(Table 5). Both series also reported the
outcomes of treatment (93, 94).
The first series enrolled 472 infants
(age, ,1 yr) with either respiratory
symptoms or vomiting and performed
fluoroscopic swallowing studies on each.
Swallowing dysfunction was detected in
63 of 472 infants (13%). Among these
infants, 70% had tracheal aspiration
and 30% had laryngeal penetration.
Because the coordination of swallowing
improves with age among infants without
chronic illnesses, the infants with
swallowing dysfunction were managed
by thickening the consistency of their
food. Tracheal aspiration or laryngeal
penetration was seen in 179 swallowing
studies with thin liquids, 61 studies with
thickened liquids, and 14 studies with
pureed food (93).
The second case series included 112
infants (age, ,1 yr) with wheezing or
intermittent stridor and performed video-
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fluoroscopic swallowing function studies on
each. Swallowing dysfunction was detected
in 13 of 112 infants (12%). Nine infants
were treated with a thickened diet, and four
infants had their oral feedings stopped and
received nasojejunal or gastrostomy
feedings temporarily. In all of the infants,
the swallowing dysfunction resolved within
3–9 months (94).
Taken together, the evidence suggests
that swallowing dysfunction, which is
known to cause wheezing, can be identified
by video-fluoroscopic swallowing studies
in 10–15% of infants who do not have
a chronic illness but have respiratory
symptoms. More than 90% of such patients
will improve with feeding interventions
while waiting for the swallowing
coordination to improve with age. Thus,
9–14% of patients who undergo video-
fluoroscopic swallowing studies may
derive some benefit. The committee has
very low confidence (i.e., quality of
evidence) in the accuracy of these
estimated effects because the study
designs were case series (i.e., they
were uncontrolled); and there
was risk for indirectness (i.e., most
series looked at infants who had a
variety of respiratory symptoms, not
specifically wheezing).
Rationale. A video-fluoroscopic
swallowing study confers several potential
benefits. Finding swallowing dysfunction
usually leads to feeding modifications that
reduce aspiration by approximately 90%;
a reduction in aspiration is a surrogate
outcome for persistent wheezing, stridor,
cough, and pneumonia. Other benefits
include relief from the burden, cost, and
potential harms of further diagnostic testing;
probable reductions in the use of ineffective
medications (bronchodilators or inhaled
corticosteroids) and the frequency of
physician visits; and parental reassurance
given the high likelihood that the condition
will spontaneously resolve. Limitations
include the need for infant/child
cooperation, cost, availability of speech
pathologist, and the risk of aspiration
during the study. The committee judged
that the desirable consequences outweigh
the undesirable consequences and,
therefore, suggests that infants with
persistent wheezing that has not
responded to conventional therapies
undergo a video-fluoroscopic swallowing
study. The recommendation is
conditional because the very low quality
of evidence provides little certainty that
the benefits of a video-fluoroscopic
swallowing study exceed the burdens,
costs, and harms.
Recommendation 8. For infants
without neurologic pathology with
persistent wheezing that is not relieved by
bronchodilators, inhaled corticosteroids, or
systemic corticosteroids, we suggest a
swallowing function study to evaluate for




A common theme throughout our
guideline development was the striking
paucity of data regarding infantile
wheezing. Despite how widespread and
common this clinical problem is, we were
unable to find any large clinical studies that
used consistent case definitions and
outcomes. Most of the studies cited were
case series, providing the lowest quality of
evidence on the GRADE scale. Given the
frequency with which infantile wheezing
occurs, there is an urgent need for more
rigorous research to be conducted in this
field.
Although we used the GRADE
methodology, we rarely had patient-
important outcomes that could be
reliably linked to performance of the
various diagnostic tests. As a result,
we presumed that treatment strategies
based on a positive test would provide
therapeutic benefit to the patient, but
this presumption and limited evidence
reduced our ability to make strong
recommendations.
One clear need for future research is
to determine whether implementation of
these tests actually leads to treatment
that improves patient-important outcomes.
Outcome measures should include both
clinical responses and parental preferences,
particularly regarding choices between
diagnostic testing and empiric treatment.
However, study design is complicated by the
fact that a substantial fraction of infants with
persistent wheeze not responsive to standard
therapies have anatomic abnormalities that
may not respond to any medical therapy.
Routine incorporation of bronchoscopy
into clinical trials could address this issue, but
likely would be problematic given the
relatively high costs and risks associated with
this procedure.
This issue highlights the fact that
many current tests involve substantial
costs and/or risks that limit widespread
use. Further research should address
whether diagnosis could be achieved by
less invasive tests, radiologic studies in
lieu of bronchoscopy for anatomic
abnormalities, or analysis of exhaled breath
to detect markers of airway infection or
reflux. Comparative effectiveness studies
and the development of clinical
pathways would also help clinicians
better evaluate infants with persistent
wheezing.
In summary, this document provides
guidelines that further two goals of
interest to the ATS. First, they will aid the
pediatric generalist or respiratory
specialist in the management of the infant
with recurrent or persistent wheeze that
does not respond to conventional
therapies. Second, they will serve to
identify the research needed to improve
diagnosis and treatment of this vulnerable
population. n
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